Sommario

• • ·Tackling the cancer epidemic

    Pagina :349

     
• • ·Dangers of direct-to-consumer advertising exposed again

    Pagina :349

     
• • ·Nivolumab: another weapon in the growing immunotherapy arsenal

    Pagina :350-351

    Gerald Falchook

     
• • ·Anti-emetics in paediatric patients receiving chemotherapy

    Pagina :351-353

    Richard J Gralla

     
• • ·Trabectedin: adding clarification rather than novelty

    Pagina :353-354

    Peter Hohenberger

     
• • ·The MAINSAIL trial: an expected failure

    Pagina :355-356

    Francesco Boccardo

     
• • ·Inhibition of IGF-1R in adrenocortical carcinoma

    Pagina :356-357

    Lawrence S Kirschner

     
• • ·Old drugs, new tricks for triple-negative breast cancer

    Pagina :357-359

    Lisa Carey

     
• • ·A lesson from vorinostat in pleural mesothelioma

    Pagina :359-360

    Marina Chiara Garassino, Silvia Marsoni

     
• • ·Redefining the standard of care in metastatic leiomyosarcoma

    Pagina :360-362

    Jonathan Noujaim, Winette T A van der Graaf, Robin L Jones

     
• • ·Minimal residual disease monitoring: a new era for childhood ALL

    Pagina :362-364

    Susanne Schnittger

     
• • ·Non-inferiority trials: why oncologists must remain wary

    Pagina :364-366

    Mauricio Burotto, Vinay Prasad, Tito Fojo

     
• • ·Adjuvant chemotherapy for rectal cancer

    Pagina :e152

    Kai-yun You, Zhuo-fei Bi, Yi-min Liu, Xing-sheng Qiu

    
• • ·Adjuvant chemotherapy for rectal cancer

    Pagina :e152

    Fausto Petrelli, Andrea Coinu, Sandro Barni

    
• • ·Adjuvant chemotherapy for rectal cancer

    Pagina :e153

    Krzysztof Bujko

    
• • ·Adjuvant chemotherapy for rectal cancer

    Pagina :e154

    Ralf-Dieter Hofheinz, Claus Rödel, Iris Burkholder, Peter Kienle

    
• • ·Adjuvant chemotherapy for rectal cancer – Authors’ reply

    Pagina :e155

    Anne J Breugom, Marloes Swets, Cornelis J H van de Velde

    
• • ·Panitumumab for locally advanced head and neck squamous-cell carcinoma

    Pagina :e156

    Hiroto Ishiki, Satoru Iwase, Naoki Shimada, Tsukuru Chiba, Kohzoh Imai

    
• • ·Radiotherapy dose and fractionation for stage III NSCLC

    Pagina :e156

    José Belderbos, Iris Walraven, Judi van Diessen, Marcel Verheij, Dirk de Ruysscher

    
• • ·Correction to Lancet Oncol 2014; 15: 856

    Pagina :e158

    
• • ·Correction to Lancet Oncol 2015; 16: 60, 61

    Pagina :e158

    
• • ·NICE guidance on axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment

    Pagina :367-368

    Nwamaka Umeweni, Boglarka Mikudina, Frances Sutcliffe, Andrew Stevens

     
• • ·NICE guidance on sipuleucel-T for asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer

    Pagina :369-370

    Rosemary Lovett, Elisabeth George, Amanda Adler

     
• • ·Possible link between hepatitis B infection and gastric cancer

    Pagina :e159

    Ricki Lewis

     
• • ·Long-lasting opioids and unintentional overdose

    Pagina :e159

    Karl Gruber

    
• • ·Goserelin reduces chemotherapy-associated ovarian failure

    Pagina :e160

    Susan Mayor

     
• • ·Medical Innovation Bill terminated

    Pagina :e160

    Rhiannon Howe

    
• • ·Whole-genome analysis of pancreatic cancer

    Pagina :e161

    Talha Khan Burki

     
• • ·First biosimilar drug approved in the USA

    Pagina :e161

    Talha Khan Burki

     
• • ·Bortezomib treatment for patients with mantle-cell lymphoma

    Pagina :e162

    Sanjay Tanday

     
• • ·Radiation in combination with immune-checkpoint inhibitors

    Pagina :e162

    Susan Mayor

    
• • ·Mutation patterns in lung cancer never-smokers

    Pagina :e163

    Karl Gruber

     
• • ·Failure to improve cancer services in the UK

    Pagina :e163

    Talha Khan Burki

    
• • ·Aromatase inhibitors may reduce endometrial cancer risk

    Pagina :e164

    Vicki Brower

     
• • ·Sunitinib benefits patients with small-cell lung cancer

    Pagina :e164

    Sanjay Tanday

    
• • ·Probiotics and cancer: ready for meal time?

    Pagina :371-372

    Janindra Warusavitarne, Justin Stebbing

      
• • ·NED (No Evidence of Disease)

    Pagina :372-373

    Aaron van Dorn

     
• • ·Cooking for patients with cancer: a practical guide

    Pagina :373-374

    Jules Morgan

     
• • ·Late Fragments

    Pagina :374

    Isabel Lokody

     
• • ·Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

    Pagina :375-384

    Jeffrey S Weber, Sandra P D’Angelo, David Minor, F Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Hoeller, Nikhil I Khushalani, Wilson H Miller, Christopher D Lao, Gerald P Linette, Luc Thomas, Paul Lorigan, Kenneth F Grossmann, Jessica C Hassel, Michele Maio, Mario Sznol, Paolo A Ascierto, Peter Mohr, Bartosz Chmielowski, Alan Bryce, Inge M Svane, Jean-Jacques Grob, Angela M Krackhardt, Christine Horak, Alexandre Lambert, Arvin S Yang, James Larkin

    Riassunto Riassunto Mappa Mappa   
• • ·Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial

    Pagina :385-394

    Hyoung Jin Kang, Susan Loftus, Arlene Taylor, Cara DiCristina, Stuart Green, Christian Michel Zwaan

    Riassunto Riassunto Mappa Mappa   
• • ·Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

    Pagina :395-405

    Bohuslav Melichar, Antoine Adenis, A Craig Lockhart, Jaafar Bennouna, E Claire Dees, Omar Kayaleh, Radka Obermannova, Angela DeMichele, Petr Zatloukal, Bin Zhang, Claudio Dansky Ullmann, Claudia Schusterbauer

    Riassunto Riassunto Mappa Mappa   
• • ·Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study

    Pagina :406-416

    Akira Kawai, Nobuhito Araki, Hideshi Sugiura, Takafumi Ueda, Tsukasa Yonemoto, Mitsuru Takahashi, Hideo Morioka, Hiroaki Hiraga, Toru Hiruma, Toshiyuki Kunisada, Akihiko Matsumine, Takanori Tanase, Tadashi Hasegawa, Shunji Takahashi

    Riassunto Riassunto Mappa Mappa   
• • ·Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial

    Pagina :417-425

    Daniel P Petrylak, Nicholas J Vogelzang, Nikolay Budnik, Pawel Jan Wiechno, Cora N Sternberg, Kevin Doner, Joaquim Bellmunt, John M Burke, Maria Ochoa de Olza, Ananya Choudhury, Juergen E Gschwend, Evgeny Kopyltsov, Aude Flechon, Nicolas Van As, Nadine Houede, Debora Barton, Abderrahim Fandi, Ulf Jungnelius, Shaoyi Li, Ronald de Wit, Karim Fizazi

    Riassunto Riassunto Mappa Mappa   
• • ·Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

    Pagina :426-435

    Martin Fassnacht, Alfredo Berruti, Eric Baudin, Michael J Demeure, Jill Gilbert, Harm Haak, Matthias Kroiss, David I Quinn, Elizabeth Hesseltine, Cristina L Ronchi, Massimo Terzolo, Toni K Choueiri, Srinivasu Poondru, Tanya Fleege, Ramona Rorig, Jihong Chen, Andrew W Stephens, Francis Worden, Gary D Hammer

    Riassunto Riassunto Mappa Mappa   
• • ·Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

    Pagina :436-446

    Xi-Chun Hu, Jian Zhang, Bing-He Xu, Li Cai, Joseph Ragaz, Zhong-Hua Wang, Bi-Yun Wang, Yue-E Teng, Zhong-Sheng Tong, Yue-Yin Pan, Yong-Mei Yin, Chang-Ping Wu, Ze-Fei Jiang, Xiao-Jia Wang, Gu-Yin Lou, Dong-Geng Liu, Ji-Feng Feng, Jian-Feng Luo, Kang Sun, Ya-Jia Gu, Jiong Wu, Zhi-Min Shao

    Riassunto Riassunto Mappa Mappa   
• • ·Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

    Pagina :447-456

    Lee M Krug, Hedy L Kindler, Hilary Calvert, Christian Manegold, Anne S Tsao, Dean Fennell, Ronny Öhman, Ruth Plummer, Wilfried E E Eberhardt, Kazuya Fukuoka, Rabab M Gaafar, Jean-Jacques Lafitte, Gunnar Hillerdal, Quincy Chu, Wieneke A Buikhuisen, Gregory M Lubiniecki, Xing Sun, Margaret Smith, Paul Baas

    Riassunto Riassunto Mappa Mappa   
• • ·Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial

    Pagina :457-464

    Patricia Pautier, Anne Floquet, Christine Chevreau, Nicolas Penel, Cécile Guillemet, Corinne Delcambre, Didier Cupissol, Frédéric Selle, Nicolas Isambert, Sophie Piperno-Neumann, Antoine Thyss, François Bertucci, Emmanuelle Bompas, Jerôme Alexandre, Olivier Collard, Sandrine Lavau-Denes, Patrick Soulié, Maud Toulmonde, Axel Le Cesne, Benjamin Lacas, Florence Duffaud, for the French Sarcoma Group

    Riassunto Riassunto Mappa Mappa   
• • ·Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study

    Pagina :465-474

    Ching-Hon Pui, Deqing Pei, Elaine Coustan-Smith, Sima Jeha, Cheng Cheng, W Paul Bowman, John T Sandlund, Raul C Ribeiro, Jeffrey E Rubnitz, Hiroto Inaba, Deepa Bhojwani, Tanja A Gruber, Wing H Leung, James R Downing, William E Evans, Mary V Relling, Dario Campana

    Riassunto Riassunto Mappa Mappa   
• • ·Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

    Pagina :e165

    Matthew G Oser, Matthew J Niederst, Lecia V Sequist, Jeffrey A Engelman

    Riassunto Riassunto Mappa Mappa  
• • ·Nomograms in oncology: more than meets the eye

    Pagina :e173

    Vinod P Balachandran, Mithat Gonen, J Joshua Smith, Ronald P DeMatteo

    Riassunto Riassunto Mappa Mappa  
• • ·Nail toxicities induced by systemic anticancer treatments

    Pagina :e181

    Caroline Robert, Vincent Sibaud, Christina Mateus, Michèle Verschoore, Cécile Charles, Emilie Lanoy, Robert Baran

    Riassunto Riassunto Mappa Mappa   
• • ·Accepting risk in the acceleration of drug development for rare cancers

    Pagina :e190

    David Ashley, David Thomas, Lia Gore, Rob Carter, John R Zalcberg, Renée Otmar, Julian Savulescu

    Riassunto Riassunto Mappa Mappa